CLINICAL SIGNIFICANCE OF THE TP53 MUTATION STATUS IN DIFFUSE LARGE B-CELL LYMPHOMA

Objective: to reveal the clinical significance of the mutation status of the TP53 gene in the group of receiving rituximab therapy patients with diffuse large B-cell lymphoma (DLBCL) in Novosibirsk.

 Material and methods. A total of 74 patients with DLBCL, who have been hospitalized at the City Hematology Center in Novosibirsk for the period 2012–2015, were examined. All patients received therapy with rituximab. The nucleotide sequence of the coding region of the TP53 gene (exons 5–10) and adjacent regions of introns was analyzed by the Sanger direct capillary sequencing. Functional analysis of the revealed mutations was carried out. The results of the patients` therapy were evaluated. 

Results and discussion. For the first time, it has been revealed in the course of the study of Russian patients with DLBCL setting that TP53 mutation status is associated with the greater incidence of B-symptoms, splenomegaly, leukemia of the lymphoma, and poor prognostic groups according to the International Prognostic Index. A tendency toward a greater frequency of achieving complete clinical and hematologic remission during the therapy was revealed in the subgroup of patients with DLBCL having a canonical sequence of a gene or a mutation in TP53 with an unproven oncogenic potential. Patients with functionally significant TP53 mutations had a lower overall survival rates. 

Conclusion. For this reason, hopefully therapeutic approaches aimed at the inactivated pathway of TP53 can further improve clinical outcomes in DLBCL.

1. Caminsky N., Mucaki E.J., Rogan P.K. Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis // F1000Res. 2014. 3. 282.

2. Cheung K-J.J., Horsman D.E., Gascoyne R.D. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target // Br. J. Haematol. 2009. 146. 257–269.

3. Diederichs S., Bartsch L., Berkmann J.C., Fröse K., Heitmann J., Hoppe C. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations // EMBO Mol. Med. 2016. 8. (5). 442-57.

4. Enomoto Y., Kitaura J., Hatakeyama K., Watanuki J., Akasaka T., Kato N. Emu/miR-125b transgenic mice develop lethal B-cell malignancies // Leukemia. 2011. 25. (12). 1849-1856.

5. Flowers C R., Sinha R., Vose J.M. Improving outcomes for patients with diffuse large B-cell lymphoma // Cancer J. Clin. 2010. 60. 393–408.

6. Krug U., Ganser А., Koeffler Н.Р. Tumour suppressor genes in normal and malignant hematopoiesis // Oncogene. 2002. 21. 3475–3495.

7. Leroy B., Fournier J.L., Ishioka C., Monti P., Inga A., Fronza G. The TP53 website: an integrative resource centre for the TP53mutation database and TP53mutant analysis // Nucl. Acids Res. 2013. 41. D962– D969.

8. Liu Y.Y. PTEN tumor suppressor plays less prognostic role than p53 tumor suppressor in diffuse large B-cell lymphoma // Leuk. Lymph. 2010. 51. (9). 1692–1698.

9. Miyazaki K. Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity // Rinsho Ketsueki. 2015. 56. (10). 2047-2055.

10. Olivier M., Hollstein М., Hainaut Р. TP53mutations in human cancers: origins, consequences, and clinical use // Spring Harb. Perspect. Biol. 2010. 2. a001008.

11. Poddubyaja I.V. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow: Media Medika, 2013. 104 p. [In Russian].

12. Soussi T., Kato S., Levy P.P., Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutation // Hum. Mutat. 2005. 25. 6-17.

13. Stefancikova L. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma // Int. J. Oncol. 2011. 39. 1413-1420.

14. Sturm I. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy // Cell Death Differ. 2003. 10. (4). 477-484.

15. Tamimi Y. The p53 mutation/deletion profile in a small cohort of the Omani population with diffuse large B-cell lymphoma // Sultan Qaboos Univ. Med. J. 2014. 14. (1). 50-58.

16. van de Schans S.A. Improving relative survival, but large remaining differences in survival for non-Hodgkin’s lymphoma across Europe and the United States from 1990 to 2004 // J. Clin. Oncol. 2011. 29. (2). 192–199.

17. Voropaeva E.N., Pospelova T.I., Voevoda M.I., Maksimov V.N. Comparative analysis of TP53 gene mutations in patients with DLBCL of Novosibirsk with data presented in IARC TP53 mutation database. Medicinskaya genetika = Medical Genetics. 2016. 15. (4). 17-20. [In Russian].

18. Voropaeva E.N., Pospelova T.I., Voevoda M.I., Maksimov V.N. Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma // Mol. Biol. (Mosc.). 2017. 51. (1). 53–60.

19. Xu-Monette Z.Y. Mutational profile and prognostic significance of TP53in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCLRituximab-CHOP Consortium Program Study // Blood. 2012. 120. 3986–3996.

20. Xu-Monette Z.Y., Medeiros L.J, Li Y., Orlowski R.Z., Andreeff M., Bueso-Ramos C.E.Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies // Blood. 2012. 119. (16). 3668–3683.

21. Young K.H., Leroy K., Møller M.B., Colleoni G.W., Sánchez-Beato M., Kerbauy F.R., Haioun C. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study // Blood. 2008. 112. (8). 3088--98.

22. Zhang M., Heldin A., Palomar-Siles M., Öhlin S., Bykov V.J.N., Wiman K.G. Synergistic rescue of nonsense mutant tumor suppressor p53 by combination treatment with aminoglycosides and Mdm2 inhibitors // Front. Oncol. 2018. 7. 323.